<DOC>
	<DOC>NCT02015793</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.</brief_summary>
	<brief_title>Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Subjects of Chinese descent with full Chinese parentage. 2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by endoscopy, radiologic evaluation, and/or histology during the Screening Period. 3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral corticosteroids and/or immunosuppressants. 4. Subject has a negative Tuberculosis (TB) Screening Assessment. 1. Subject with ulcerative colitis or indeterminate colitis. 2. Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future. 3. Subject with an ostomy or ileoanal pouch. 4. Subject who has short bowel syndrome. 5. Subject with symptomatic known obstructive strictures. 6. Subject with an internal or external fistula (with the exception of an anal fistula without abscess). 7. Chronic recurring infections or active TB.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>